EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Protective Effects of Imeglimin Against Oxaliplatin‐Induced Peripheral Neurotoxicity: Evidence From In Vitro and In Vivo Studies

Yusuke Koura, Kano Kinjo, Keisuke Mine iD, Yusuke Mori, Mami Ueda, Risa Kaneko, Yuna Kamiya, Taiga Sonoda, Haruka Mimata, Shunsuke Fujita iD, Takehiro Kawashiri, Daisuke Kobayashi

Journal of Applied Toxicology · 05.06.2026

DOI: 10.1002/jat.70263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Applied Toxicology, online erschienen am 05.06.2026. Verfasst von Yusuke Koura und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxaliplatin is a platinum‐based anticancer agent widely used for gastrointestinal malignancies; however, it is known to cause dose‐dependent peripheral neuropathy (OIPN), a characteristic adverse effect. OIPN results in a reduced quality of life and often necessitates dose reduction or discontinuation of oxaliplatin; however, effective preventive strategies for OIPN have yet to be established. Imeglimin, an oral antidiabetic agent belonging to the glimin class, has been suggested to influence key aspects of cellular energy metabolism. Because metformin, which shares structural and mechanistic features with imeglimin, prevents OIPN and exhibits unique pharmacological actions, we investigated whether imeglimin also prevents OIPN using both in vitro and in vivo models. In vitro, imeglimin attenuated oxaliplatin‐induced cell death, axonal shortening, and oxidative stress in F11 neuronal cells. In vivo, imeglimin prevented reductions in withdrawal thresholds to mechanical stimulation and mitigated sciatic nerve axonal injury in a rat OIPN model. Importantly, imeglimin did not diminish the cytotoxicity of oxaliplatin in several cancer cell lines or its antitumor efficacy in tumor‐bearing mice. These findings suggest that imeglimin may prevent OIPN without compromising the antitumor activity of oxaliplatin.

Schlagwörter

Stichwörter der Autor:innen

adverse effectdrug‐repositioningimegliminoxaliplatinperipheral neuropathy

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

ORCID-Profile: Keisuke Mine, Shunsuke Fujita

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Koura, Y., Kinjo, K., Mine, K., Mori, Y., Ueda, M., Kaneko, R., Kamiya, Y., Sonoda, T., Mimata, H., Fujita, S., Kawashiri, T., & Kobayashi, D. (2026). Protective Effects of Imeglimin Against Oxaliplatin‐Induced Peripheral Neurotoxicity: Evidence From In Vitro and In Vivo Studies. Journal of Applied Toxicology. https://doi.org/10.1002/jat.70263

Vancouver

Koura Y, Kinjo K, Mine K, Mori Y, Ueda M, Kaneko R, et al. Protective Effects of Imeglimin Against Oxaliplatin‐Induced Peripheral Neurotoxicity: Evidence From In Vitro and In Vivo Studies. Journal of Applied Toxicology. 2026. doi:10.1002/jat.70263

BibTeX
@article{Koura2026,
  author = {Koura, Yusuke and Kinjo, Kano and Mine, Keisuke and Mori, Yusuke and Ueda, Mami and Kaneko, Risa and Kamiya, Yuna and Sonoda, Taiga and Mimata, Haruka and Fujita, Shunsuke and Kawashiri, Takehiro and Kobayashi, Daisuke},
  title = {Protective Effects of Imeglimin Against Oxaliplatin‐Induced Peripheral Neurotoxicity: Evidence From In Vitro and In Vivo Studies},
  journal = {Journal of Applied Toxicology},
  year = {2026},
  doi = {10.1002/jat.70263}
}
Kostenlos starten →